Table 1.
Serum levels of IGFBP-2 by case-control status and levels of other variables.
| N | Mean serum IGFBP-2 (IQR) in cases | N | Mean serum IGFBP-2 (IQR) in controls | |
|---|---|---|---|---|
| All subjects | 275 | 211.4 (147.9–315.7) | 275 | 225.0 (149.7–347.9) |
| BMI | ||||
| Normal (<25 kg/m2) | 90 | 315.5 (193.1–427.6) | 79 | 320.5 (187.9–433.0) |
| Overweight/obese (≥25 kg/m2) | 184 | 176.7 (135.3–257.4) | 195 | 198.6 (137.4–297.3) |
| p difference < 0.001 | p difference < 0.001 | |||
| HT Use | ||||
| Nonusers of HT | 139 | 244.7 (147.1–341.0) | 160 | 241.5 (174.8–376.4) |
| Unopposed estrogen | 62 | 191.9 (143.7–315.4) | 59 | 158.3 (127.0–311.4) |
| Progestin + estrogen | 74 | 187.4 (148.8–262.9) | 56 | 191.9 (140.9–296.7) |
| p difference = 0.04 | p difference = 0.004 | |||
| History of diabetes | ||||
| No | 259 | 219.6 (148.5–317.3) | 258 | 229.8 (152.9–360.1) |
| Yes | 16 | 185.0 (124.8–273.1) | 17 | 157.7 (139.6–193.1) |
| p difference = 0.33 | p difference = 0.01 | |||
| Age at baseline | ||||
| <Median (62 yrs) | 140 | 189.5 (136.5–284.1) | 137 | 187.9 (136.8–281.7) |
| ≥Median (62 yrs) | 135 | 246.3 (153.0–339.6) | 138 | 277.9 (180.4–400.0) |
| p difference = 0.01 | p difference < 0.001 | |||
| Race | ||||
| White | 238 | 219.9 (149.5–328.5) | 238 | 232.0 (154.7–362.8) |
| Black | 22 | 145.6 (110.2–264.7) | 22 | 181.1 (126.7–246.5) |
| Other | 15 | 235.7 (153.0–283.5) | 15 | 187.6 (145.8–347.9) |
| p difference = 0.08 | p difference = 0.05 | |||
| Smoking status | ||||
| Never | 134 | 214.8 (150.1–338.7) | 149 | 235.8 (156.5–364.4) |
| Ever | 141 | 211.4 (144.0–309.5) | 126 | 205.0 (147.4–311.4) |
| p difference = 0.40 | p difference = 0.24 |